trending Market Intelligence /marketintelligence/en/news-insights/trending/k_nqeyw7r9k916fpwvg2ra2 content esgSubNav
In This List

Teva taps senior VP to lead generic-drug unit

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Teva taps senior VP to lead generic-drug unit

Teva Pharmaceutical Industries Ltd. has appointed John Nason to lead its Teva Active Pharmaceutical Ingredients unit, the leading global provider of active pharmaceutical ingredients.

As president, Nason will oversee the Teva unit that manufactures generic drugs and a portfolio of specialty medicines. He will be based in Teva's global headquarters in Petach Tikva, Israel.

Nason has worked for Teva since 2015 as senior vice president of European technical operations. According to the company's Sept. 5 statement, he worked at Bristol-Myers Squibb Co. for 12 years prior to his time with Teva.